Accessibility Menu
Hyperion DeFi logo

Hyperion DeFi(NASDAQ) EYEN

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-100%
5 Year-99%
1 Year-68%
1 Month-16%
N/A
Hyperion DeFi last closing stock price
MetricPriceDate
Last closeUSD 2.642026-07-31
Hyperion DeFi stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.18%USD 2.512026-07-24
1 month-15.92%USD 3.142026-07-01
3 month-36.84%USD 4.182026-05-01
Year to date-25.84%USD 3.562025-12-31
1 year-68.04%USD 8.262025-07-31
3 year-98.42%USD 167.202023-08-01
5 year-99.22%USD 338.402021-07-30
Since inception-99.66%USD 793.602018-01-25

Hyperion DeFi Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.04M

Net Income (TTM)

-$46.99B

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Aug 11, 2025

EYEN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Hyperion DeFi

Eyenovia, Inc. is a biotechnology company focused on developing treatments for eye diseases. It leverages innovative microdosing technology to enhance drug delivery and improve patient outcomes. Driven by a strong leadership team, Eyenovia aims to address unmet needs in ophthalmology through a growing pipeline of targeted therapeutics.

Products and Services

Optejet®: A microdosing platform for precise ocular drug delivery.

Therapeutic pipeline targeting essential ophthalmic conditions.

Partnerships and collaborations to expand market reach and resource access.

What Makes Eyenovia, Inc. Special

Eyenovia stands out due to its Optejet® microdosing technology, which enhances drug delivery precision and patient adherence compared to traditional eye drop methods. This unique platform positions the company as a leader in patient-centric ophthalmic solutions.

Five Things You Need to Know

Eyenovia focuses on innovative drug delivery methods for eye care.

Optejet® technology improves the efficiency of medication application.

Strong pipeline addressing significant ophthalmic needs.

Strategic partnerships bolster development and commercialization efforts.

Commitment to expanding the applications of its platform technology.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

9

CEO

Hyunsu Jung

Website

www.eyenovia.com

Headquarters

New York City, NY 10017, US

EYEN Financials

Key Financial Metrics (TTM)

Gross Margin

63.68%

Operating Margin

-2012.57%

Net Income Margin

-3163.01%

Return on Equity

-63.54%

Return on Capital

-38.29%

Return on Assets

-47.08%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

-2.41%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$510.32M

Operating Income

-$20.99M

EBITDA

$648.68M

Operating Cash Flow

-$14.77B

Capital Expenditure

$0.00

Free Cash Flow

-$14.77B

Cash & ST Invst.

$7.38M

Total Debt

$9.07M

Hyperion DeFi Performance Analysis

Hyperion DeFi annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 3,787N/A
20242024-12-31USD 57,3361414.0%
20252025-12-31USD 813,4551318.8%
Hyperion DeFi sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-101.5%
Q32025-09-30133952.2%
Q42025-12-3164.0%
Q12026-03-31-50.8%
Hyperion DeFi annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -66.5971.5%
20232023-12-31USD -53.15-20.2%
20242024-12-31USD -59.8112.5%
20252025-12-31USD -9.40-84.3%
Hyperion DeFi sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3018.3%
Q32025-09-30102.2%
Q42025-12-31-8684.6%
Q12026-03-31105.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$244.27K

+1559.4%

Gross Profit

$244.27K

+1564.9%

Gross Margin

100.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

13

N/A

Net Income

$8.84M

+353.8%

EBITDA

-$4.99M

-76.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$7.38M

+87.6%

Total Debt

$9.07M

-18.6%

Accounts Receivable

$351.06K

+25.9%

Inventory

$0.00

N/A

Long Term Debt

$7.10M

+1087.6%

Short Term Debt

$1.97M

-81.3%

Return on Assets

-47.08%

N/A

Return on Invested Capital

-32.00%

N/A

Free Cash Flow

-$4.20M

+5.5%

Operating Cash Flow

-$4.20M

+5.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CERCCerecor Inc.
$2.93-1.68%
LUMOLumos Pharma, Inc.
$4.34+0.00%
STSASatsuma Pharmaceuticals, Inc.
$1.10+0.00%
PSTIPluristem Therapeutics Inc.
$1.00-2.91%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About EYEN

What is the current price of Hyperion DeFi?

Hyperion DeFi is trading at N/A per share.

What is the 52-week range for Hyperion DeFi?

Over the past 52 weeks, Hyperion DeFi has traded between N/A and N/A.

How much debt does Hyperion DeFi have?

As of the most recent reporting period, Hyperion DeFi reported total debt of $9.07M.

How much cash does Hyperion DeFi have on hand?

Hyperion DeFi reported $7.38M in cash and cash equivalents in its most recent financial results.

What is Hyperion DeFi’s dividend yield?

Hyperion DeFi does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services